PLC and CardioGenesis settle patent litigation and agree financial terms over TMR procedures
This article was originally published in Clinica
PLC Systems and CardioGenesis have settled all patent litigation relating to PLC's heart-synchronised laser technology for use in transmyocardial revascularisation procedures (TMR).
You may also be interested in...
Cilta-cel maintained high response rates in longer-term multiple myeloma data, but ide-cel causes less cytokine release syndrome and severe neurotoxicity – and it has a March decision date at the US FDA.
Our updated graphic tracker of key developments from the leading vaccine candidates.
Pathway open for drug as post-covalent BTK option as Loxo gears up for "risky" Phase III head-to-head study in Q1 2021.